日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

FedECA: federated external control arms for causal inference with time-to-event data in distributed settings

FedECA:分布式环境下基于生存时间数据的因果推断的联邦外部控制机构

Ogier du Terrail, Jean; Klopfenstein, Quentin; Li, Honghao; Mayer, Imke; Loiseau, Nicolas; Hallal, Mohammad; Debouver, Michael; Camalon, Thibault; Fouqueray, Thibault; Arellano Castro, Jorge; Yanes, Zahia; Dahan, Laëtitia; Taïeb, Julien; Laurent-Puig, Pierre; Bachet, Jean-Baptiste; Zhao, Shulin; Nicolle, Remy; Cros, Jérôme; Gonzalez, Daniel; Carreras-Torres, Robert; Garcia Velasco, Adelaida; Abdilleh, Kawther; Doss, Sudheer; Balazard, Félix; Andreux, Mathieu

Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period

在日本2型糖尿病患者中,伊美格列明联合胰岛素单药治疗的疗效和安全性(TIMES 3):一项随机、双盲、安慰剂对照的3期临床试验,并设有36周的开放标签扩展期

Reilhac, Caroline; Dubourg, Julie; Thang, Carole; Grouin, Jean-Marie; Fouqueray, Pascale; Watada, Hirotaka

Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial

在日本2型糖尿病患者中,伊美格列明单药治疗或与现有降糖药物联合治疗的长期安全性和有效性(TIMES 2):一项为期52周、开放标签、多中心3期临床试验

Dubourg, Julie; Fouqueray, Pascale; Quinslot, Damien; Grouin, Jean-Marie; Kaku, Kohei

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy

直接 AMP 激酶激活剂 PXL770 在 X 连锁肾上腺脑白质营养不良的体外和体内模型中的有益作用

Pierre-Axel Monternier ,Parveen Parasar ,Pierre Theurey ,Pascale Gluais Dagorn ,Navtej Kaur ,Tavarekere N Nagaraja ,Pascale Fouqueray ,Sébastien Bolze ,David E Moller ,Jaspreet Singh ,Sophie Hallakou-Bozec

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects

伊美格列明在白种人和日本健康受试者中的药代动力学

Fouqueray, Pascale; Chevalier, Clémence; Bolze, Sébastien

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity

针对2型糖尿病患者的伊美格列明II期临床试验表明,该药物对胰岛素分泌和敏感性有影响。

Theurey, Pierre; Thang, Carole; Pirags, Valdis; Mari, Andrea; Pacini, Giovanni; Bolze, Sébastien; Hallakou-Bozec, Sophie; Fouqueray, Pascale

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.

伊美格列明降低乳酸性酸中毒风险:与二甲双胍的比较

Theurey Pierre, Vial Guillaume, Fontaine Eric, Monternier Pierre-Axel, Fouqueray Pascale, Bolze Sébastien, Moller David E, Hallakou-Bozec Sophie

Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study

直接激活AMP激酶对胰岛素抵抗和非酒精性脂肪肝患者的药效学影响:一项1b期研究

Fouqueray, Pascale; Bolze, Sebastien; Dubourg, Julie; Hallakou-Bozec, Sophie; Theurey, Pierre; Grouin, Jean-Marie; Chevalier, Clémence; Gluais-Dagorn, Pascale; Moller, David E; Cusi, Kenneth

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial

伊美格列明治疗日本2型糖尿病患者的疗效和安全性:一项为期24周的随机、双盲、安慰剂对照、剂量范围探索的2b期试验

Dubourg, Julie; Ueki, Kohjiro; Grouin, Jean-Marie; Fouqueray, Pascale

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

伊美格列明的作用机制:一种治疗2型糖尿病的新型药物

Hallakou-Bozec, Sophie; Vial, Guillaume; Kergoat, Micheline; Fouqueray, Pascale; Bolze, Sébastien; Borel, Anne-Laure; Fontaine, Eric; Moller, David E